FDAnews Announces — New Management Report — Drug or Device? How the 21st Century Cures Act Impacts Combination Products

Share Article

Combination products remain one of the most difficult regulatory challenges for life sciences innovators. Drug or Device? How the 21st Century Cures Act Impacts Combination Products offers practical advice on the newest changes in the law on combination products and a look around the corner at how sponsors of combination products should seek to position their products to ensure a least burdensome and optimal regulatory pathway.

Drug or Device? How the 21st Century Cures Act Impacts Combination Products
**An FDAnews Management Report**
http://www.fdanews.com/drugordevice    

Combination products remain one of the most difficult regulatory challenges for life sciences innovators.

Which FDA Center has the lead?

Will the product need one marketing application or two?

Will a drug need to be cross-labeled and approved for use with a device?

These and many more questions can make combination product sponsors feel like they are entering an unforgiving regulatory labyrinth.

The 21st Century Cures Act requires the FDA, over the next several years, to issue guidance that will create a structured process and best practices for managing the development and reviews of drug/device/biologic combinations. The law provides for a streamlined approach to GMP for combination products similar to what the agency has recently announced through rule and guidance.

Drug or Device? How the 21st Century Cures Act Impacts Combination Products takes a close look at the FDA’s new authority governing combination products, as well as several new provisions under the 21st Century Cures Act that could usher in a new era of interdisciplinary product reviews at the FDA. Readers will learn:

  •     How the 21st Century Cures Act defines primary mode of action
  •     How to use pre-RFD (Request for Designation) meetings with the FDA to hammer out a customized review process that meets the sponsor’s needs
  •     How the FDA will determine which center (CDER, CDRH, CBER) will take the lead on reviewing combination product applications
  •     Whether FDA will apply a “least burdensome” approach or require sponsors to undertake twice the usual amount of work
  •     What a manufacturers rights and remedies are if they feel that their combination product is not being handled properly by the FDA

Order Drug or Device? How the 21st Century Cures Act Impacts Combination Products for practical advice on the newest changes in the law on combination products and a look around the corner at how sponsors of combination products should seek to position their products to ensure a least burdensome and optimal regulatory pathway.

Who Will Benefit:

  •     Design team
  •     Regulatory affairs/legal
  •     Research and development

FDAnews Management Report Details:
Drug or Device? How the 21st Century Cures Act Impacts Combination Products
Price: $397
http://www.fdanews.com/drugordevice    

Easy Ways to Order:
Online: http://www.fdanews.com/drugordevice        
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website